Provider notes

• NMUH:
• Non-formulary
• RFL:
• Non-formulary
• RNOH:
• Complex spinal fusion surgeries in line with NHSE commissioning policy
• This product is currently unavailable in the UK
• UCLH:
• WH:
• Non-formulary

Provider notes

• NMUH:
  • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when in line with NICE recommendations and/or Local Trust Guidelines.
  • See links below
• RFL:
  • No restriction stated
• RNOH:
  • No restriction stated
• UCLH:
• WH:
  • No restriction stated

Provider notes

• NMUH:
  • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • See link below
  • To be initiated by rheumatologists only
• RFL:
  • No restriction stated
• RNOH:
  • No restriction stated
• UCLH:
• WH:
  • Tabs 5mg only (daily preparation)

Provider notes

• NMUH:
  • Non-formulary
• RFL:
  • Non-formulary
• RNOH:
  • No restriction stated
• UCLH:
• WH:
  • Non-formulary

Approved as second-line adjuvant therapy for post-menopausal (including those for whom it is chemically induced) women with breast cancer to prevent bone recurrence and cancer mortality, for patients without IV access/zolendronic acid toxicity (JFC February 2019).

Provider notes

• NMUH:
  • 1st line bisphosphonate for the Prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.
• RFL:
  • See above
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • As above

Provider notes

• NMUH:
  • Non-formulary
• RFL:
  • Non-formulary
• RNOH:
  • No restriction stated
• UCLH:
• WH:
  • Non-formulary

Provider notes

• NMUH:
  • See links below
  • See MHRA Drug Safety Updates
• RFL:
  • No restriction stated
• RNOH:
  • No restriction stated
• UCLH:
• WH:
  • No restriction stated

Not a preferred choice for adjuvant breast cancer; intravenous zolendronic acid and oral ibrandronic acid are preferred agents (JFC February 2019)

Provider notes

• NMUH:
  • 400mg and 800mg tablets only
• RFL:
  • 400mg, 800mg and 520mg tablets
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • Non-formulary

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

• NMUH:
  
  • We stock the generic zoledronic acid preparation - 4mg/5ml for all indications where zoledronic acid is required. See link below for further details.
  • Check MHRA Drug Safety Updates
• RFL:
  
  • No restriction stated
• RNOH:
  
  • No restriction stated
• UCLH:
• WH:
  
  • No restriction stated

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for adjuvant therapy for post-menopausal (including those for whom it is chemically induced) women with breast cancer to prevent bone recurrence and cancer mortality [unlicensed indication] (JFC February 2016)

Provider notes

• NMUH:
• RFL:
  
  • Approved for treatment of hypercalcaemia of malignancy 1st line.
  • For prevention of skeletal-related events in patients who have bone metastases.
  • For the prevention of skeletal-related events zoledronic acid is prescribed on Chemocare. (RFL electronic chemotherapy prescribing system)
  • Approved for adjuvant therapy for post-menopausal (including those for whom it is chemically induced) women with breast cancer to prevent bone recurrence and cancer mortality [unlicensed indication] (JFC February 2016)
    • For adjuvant indication -this is prescribed on Chemocare (RFL electronic chemotherapy prescribing system)
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Added to the NCL Joint Formulary as an adjuvant treatment for post-menopausal women with early breast cancer (Feb 2016)

(hospital only prescribing) for osteoporotic men or women with renal impairment

for osteoporotic women when used in line with NICE TA

Approved for osteoporosis in women (see NICE TA) and men unable to take oral bisphosphonates (either due to intolerance or unable to comply with administration instructions) and unable to receive IV zoledronic acid due to renal dysfunction (JFC October 2017)

Provider notes

• NMUH:
  
  • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • See links below
  • To be prescribed by Rheumatology and Care of the Elderly Consultants ONLY.
  • Check MHRA Drugs Safety Updates
• RFL:
  
  • Approved for osteoporosis treatment in line with NICE TA by Endocrinology and Rheumatology
  • See links below
• RNOH:
  
  • See links below for Transfer of Care Guideline and Template Letter with Hertfordshire
• UCLH:
• WH:
  
  • Also approved for osteoporosis in men unable to take oral bisphosphonates and unable to receive IV zoledronic acid due to renal dysfunction (November 2017)

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for preventing skeletal related events for oncology patients subject to service redevelopment (November 2015)

Provider notes

• NMUH:
  
  • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • See links below
  • To be prescribed by the Oncology team ONLY.
  • Check MHRA Drugs Safety Updates
• RFL:
  
  • As per NICE TA265.
    
    
    • This drug must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
• RNOH:
  
  • Giant cell tumour of bone
• UCLH:
• WH:
  
  • No restriction stated

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for hypercalcaemia of malignancy who are either refractory to bisphosphonates or have creatinine clearance <30mL/min in whom bisphosphonates are contraindicated (JFC August 2018).

Only on the advice of oncology or palliative care consultants.

Provider notes

• NMUH:
• As per above agreed indication
• RFL:
• As per above agreed indication
• RNOH:
• Non-formulary
• UCLH:
• WH:
• As above